Levodopa/Carbidopa Stada (Carbidopa, Levodopa)

Levodopa/Carbidopa is used in the management of Parkinsonian disorders by restoring dopaminergic activity in the central nervous system.

• Parkinson's disease: reduces bradykinesia, rigidity, and resting tremor, improving motor function.
• Parkinsonian syndrome: alleviates motor symptoms in secondary parkinsonism and drug‑induced parkinsonism.
• Levodopa‑responsive tremor: provides symptomatic relief of resting tremor that responds to dopaminergic therapy.

• Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine within the central nervous system. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, preventing conversion of levodopa to dopamine outside the brain. This increases the amount of levodopa reaching the CNS, enhancing central dopamine concentrations and mitigating the dopamine deficiency characteristic of Parkinsonian states.

Levodopa/Carbidopa may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Vomiting
• Dizziness or light‑headedness
• Orthostatic hypotension
• Headache
• Insomnia

Serious or Rare Side Effects

• Dyskinesia (involuntary movements)
• Hallucinations or psychosis
• Severe hypotension or syncope
• Cardiac arrhythmias
• Neuroleptic malignant syndrome
• Severe allergic reactions (rash, angioedema)

When prescribing Levodopa/Carbidopa, clinicians should observe several safety considerations to minimize risks.

• Blood pressure monitoring: watch for orthostatic hypotension, especially during dose initiation or escalation.
• Dose adjustment in renal impairment: reduce dose in patients with severe renal dysfunction.
• Psychiatric assessment: evaluate for history of hallucinations, psychosis, or depression before treatment.
• Avoid abrupt discontinuation: taper gradually to prevent withdrawal and neuroleptic malignant syndrome.
• Use caution in the elderly: start with low doses and titrate slowly due to increased sensitivity.
• Store at room temperature: keep below 25 °C in the original container, protect from moisture and light.

Levodopa/Carbidopa can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective monoamine oxidase inhibitors (MAO‑I): risk of hypertensive crisis.
• Antipsychotic drugs that block dopamine receptors (e.g., haloperidol, risperidone): may diminish therapeutic effect.
• High‑dose pyridoxine (vitamin B6): accelerates peripheral conversion of levodopa, reducing central availability.

Moderate Interactions (Monitor Closely)

• Selective MAO‑B inhibitors (e.g., selegiline, rasagiline): may increase dopaminergic activity, requiring dose adjustment.
• Antihypertensive agents (especially alpha‑blockers): additive hypotensive effect.
• Iron or antacid preparations: may decrease levodopa absorption; separate administration by at least 2 hours.
• SSRIs and SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors.